We are live on ! Find out more
STAB

Statera Biopharma, Inc. Common Stock
STAB

Delisted

STAB was delisted on the 11th of January, 2023.

Back to rankings

19 hedge funds and large institutions have $661K invested in Statera Biopharma, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

12% more funds holding

Funds holding: 17 → 19 (+2)

38% less capital invested

Capital invested by funds: $1.07M → $661K (-$408K)

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
19
Holders Change
+2
Holders Change %
+11.76%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$34.5K
2
Millennium Management
Millennium Management
New York
+$23.6K
3
UBS Group
UBS Group
Switzerland
+$17K
4
Morgan Stanley
Morgan Stanley
New York
+$13.9K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$153K
2
Barclays
Barclays
United Kingdom
-$84.9K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$11.5K
4
Wells Fargo
Wells Fargo
California
-$974
5
BRWA
B. Riley Wealth Advisors
Florida
-$834
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$407K -$153K -66,500 -24%
Vanguard Group
2
Vanguard Group
Pennsylvania
$104K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$34K – – –
BRWA
4
B. Riley Wealth Advisors
Florida
$33K -$834 -362 -2%
PNC Financial Services Group
5
PNC Financial Services Group
Pennsylvania
$30K +$34.5K +15,000 New
Barclays
6
Barclays
United Kingdom
$15K -$84.9K -36,850 -83%
UBS Group
7
UBS Group
Switzerland
$15K +$17K +7,398 New
Morgan Stanley
8
Morgan Stanley
New York
$12K +$13.9K +6,047 +6,047%
Royal Bank of Canada
9
Royal Bank of Canada
Ontario, Canada
$7K -$11.5K -5,000 -58%
Carson Wealth (CWM LLC)
10
Carson Wealth (CWM LLC)
Nebraska
$2K – – –
BlackRock
11
BlackRock
New York
$1K – – –
AIC
12
Archer Investment Corporation
Indiana
$591 – – –
FDCDDQ
13
Federation des caisses Desjardins du Quebec
Quebec, Canada
$197 – – –
Millennium Management
14
Millennium Management
New York
$20 +$23.6K +10,267 New
Wells Fargo
15
Wells Fargo
California
– -$974 -423 -93%
Bank of America
16
Bank of America
North Carolina
– -$25 -11 -10%

STAB Hedge Fund Activity: Q3 2020 in Review

19 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q3 2020, worth a combined $661K — down 38% from $1.07M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new STAB positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 6 trimmed.

The largest buyer was PNC Financial Services Group, opening a new position worth an estimated $34.5K. The largest seller was Renaissance Technologies, cutting an estimated $153K.

  • 19 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q3 2020, up from 17 in Q2 2020.
  • Funds reported $661K of Statera Biopharma, Inc. Common Stock stock for Q3 2020, down 38% quarter-over-quarter.
  • 3 funds opened new Statera Biopharma, Inc. Common Stock positions in Q3 2020 and 1 closed out, a net change of +2 holders.
  • The largest Statera Biopharma, Inc. Common Stock buyer in Q3 2020 was PNC Financial Services Group, an estimated $34.5K added.
  • The largest Statera Biopharma, Inc. Common Stock seller in Q3 2020 was Renaissance Technologies, an estimated $153K sold.

Based on aggregated 13F filings for Q3 2020.